Harvard Bioscience, Inc. Reports Second Quarter 2023 Net Loss of $980,000
Company Generates Revenues of $28.8 Million in Q2 2023
Harvard Bioscience, Inc.(HBIO) has released its unaudited consolidated financial statements for the second quarter ended June 30, 2023, revealing a net loss of $980,000 and total revenues of $28.8 million. The company's financial performance is analyzed in detail across various categories in its balance sheet, income statement, and cash flow statement.
Consolidated Balance Sheets
Harvard Bioscience's consolidated balance sheet as of June 30, 2023, shows total assets amounting to $142.9 million. The company's current assets, including cash and cash equivalents, accounts receivable, inventories, and other current assets, amounted to $52.6 million. Property, plant, and equipment netted at $3.5 million, while goodwill and intangible assets stood at $56.8 million and $18.4 million, respectively.
